Meeting
2023 ASCO Annual Meeting
Exploratory novel biomarker and resistance mechanism of milademetan, an MDM2 inhibitor, in amplified MDM2 intimal sarcoma from an open-label phase 1b/2 trial (NCCH1806/MK004).
Authors
Takafumi Koyama
Department of Experimental Therapeutics, National Cancer Center Hospital, Tokyo, Japan
Takafumi Koyama , Toshio Shimizu , Yuki Kojima , Kazuki Sudo , Hitomi Sumiyoshi Okuma , Tatsunori Shimoi , Hitoshi Ichikawa , Shinji Kohsaka , Akihiko Yoshida , Naoko Matsui , Kenichi Nakamura , Noboru Yamamoto , Kan Yonemori
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Sarcoma
Track
Sarcoma
Sub Track
Molecular Targets/Biomarkers/Tumor Biology
Clinical Trial Registration Number
JMA-IIA00402
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 11544)
DOI
10.1200/JCO.2023.41.16_suppl.11544
Abstract #
11544
Poster Bd #
478
Abstract Disclosures
Similar Posters
Poster
2019 Gastrointestinal Cancers Symposium
Genomic alterations in appendiceal carcinoma using circulating DNA.
First Author: Walid Labib Shaib
Poster
2022 ASCO Annual Meeting
Next-generation sequencing (NGS) for identifying actionable molecular alterations in patients with newly diagnosed and recurrent IDHwt-glioblastoma (GBM): A large mono-institutional experience.
First Author: Marta Padovan
Poster
2021 ASCO Annual Meeting
Circulating tumor DNA (ctDNA) in patients with advanced adrenocortical carcinoma.
First Author: Bassel Nazha
Poster
2021 ASCO Annual Meeting
Prevalence of hyperprogressive disease (HPD) mutations and correlations to immune-related biomarkers in a large pan-cancer Chinese cohort.
First Author: Shengli Yang